Wave Life Sciences (WVE, Financial) reported first-quarter revenue of $9.175 million, falling short of the expected $11.34 million. Despite this, the company is making significant progress in its clinical trials. In the field of obesity, dosing has been completed for the first cohorts in the INLIGHT trial, and advancements are being made in the RestorAATion-2 trial focused on Alpha-1 antitrypsin deficiency (AATD). Further data from these trials are expected later this year, showcasing Wave's expertise in RNA therapies.
The RestorAATion-2 trial is centered around WVE-006, an RNA editing treatment administered subcutaneously. This trial is expected to yield data from various dose cohorts within the year, highlighting the potential of WVE-006 alongside Wave's other GalNAc-conjugated RNA editing programs. Additionally, the company is conducting the INLIGHT trial for WVE-007, a GalNAc-siRNA therapy targeting obesity, with initial clinical data anticipated in the year's latter half. This treatment aims to offer a revolutionary approach to managing obesity, promoting healthy weight loss and the maintenance of muscle mass, with the convenience of infrequent dosing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.